Scholar Rock Announces Appointment of Lisa Amaya Price as Senior Vice President, Human Resources
11 avr. 2019 07h00 HE
|
Scholar Rock
CAMBRIDGE, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress
18 mars 2019 17h31 HE
|
Scholar Rock
Initiated and Progressed Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers, Transitioning to a Clinical-Stage CompanyPresented Compelling Preclinical Data from the SRK-181 Cancer Immunotherapy...
Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGFβ1 Activation, to Overcome Checkpoint Inhibitor Resistance
12 mars 2019 16h30 HE
|
Scholar Rock
Selective inhibition of TGFβ1 activation enables immune cell entry into the tumor microenvironment in preclinical models, demonstrating potential for overcoming a key mechanism of primary resistance...
Scholar Rock to Participate in Upcoming Investor Conferences
06 mars 2019 07h00 HE
|
Scholar Rock
CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in...
Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans
26 févr. 2019 07h00 HE
|
Scholar Rock
Favorable Safety Profile Across All Tested Doses Supports Initiation of a Phase 2 Trial in Patients with Spinal Muscular Atrophy (SMA)Pharmacodynamic Results Demonstrate Robust and Sustained Target...
Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference
03 janv. 2019 08h00 HE
|
Scholar Rock
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy
03 déc. 2018 16h05 HE
|
Scholar Rock
CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
29 nov. 2018 16h05 HE
|
Scholar Rock
CAMBRIDGE, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces Publication of Preclinical Data on the Therapeutic Benefit of Inhibiting Myostatin Activation in Models of Spinal Muscular Atrophy
27 nov. 2018 07h00 HE
|
Scholar Rock
CAMBRIDGE, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces the Addition of Edward (Ted) Myles to Its Board of Directors
19 nov. 2018 16h05 HE
|
Scholar Rock
CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...